A report in Bioshares (1 June 2020) included, "This is an opportunity for Admedus, either directly with its own TAVR device, or through
the outlicensing of ADAPT to market leaders such as Edwards Life Sciences and Medtronic ..........."
I am not expecting any major development from AVR before the end of the Covid-19 crisis, but with AVR having already garnered interest
from other MedTech companies one would have to think there will eventually be a collaboration of some kind.
That would revive the share price.
Possible partners, page-10
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.31 |
Change
-0.240(1.29%) |
Mkt cap ! $351.9M | |||
| Open | High | Low | Value | Volume |
| $18.80 | $19.15 | $18.20 | $159.7K | 8.611K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 73 | $18.31 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.33 | 90 | 1 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| AVR (ASX) Chart |